PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Both yoy net incomes decline, with AVXL at -24.83%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.10%
D&A growth of 3.10% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Negative yoy SBC while AVXL is 24.25%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
292.72%
Well above AVXL's 136.25% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
AP growth well above AVXL's 192.80%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
292.72%
Growth well above AVXL's 65.83%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-67.58%
Negative yoy while AVXL is 65.12%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-21.90%
Both yoy CFO lines are negative, with AVXL at -2.79%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-11.48%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Negative yoy issuance while AVXL is 155.76%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.